Deal-making vital for pharma companies to offset R&D costs, says report

Deal-making is becoming increasingly vital for pharmaceutical companies to offset rising research and development costs, according to new research.

A report by business intelligence provider, GBI Research, states that pharma companies are considering various strategies to overcome current challenges thrown up by shifts in patent laws and the global economy.

Analyst Priyatham Salimadugu said: “Deal activity can help pharma firms to enhance their research and regulatory approaches and can aid portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization and sales.”